Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sangamo licenses Biogen Idec rights to hemoglobinopathy treatments; rights transferred to Bioverativ

Executive Summary

Sangamo BioSciences Inc. (therapeutic DNA-binding proteins) licensed Biogen Idec Inc. exclusive worldwide rights to develop and commercialize treatments for sickle cell disease (SCD) and beta-thalassemia. Biogen also received an exclusive, royalty-bearing license--with the right to sublicense--to Sangamo’s zinc finger nuclease (ZFN) technology platform, plus a nonexclusive, worldwide, royalty-free license--and sublicensing rights--to certain other IP developed under the agreement.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies